Bramble: Retatrutide https://news.ketelle.co.uk/entities/retatrutide Stories involving Retatrutide, told neutrally, with how each side covers them. en-gb Real-world study: people switching from weight-loss jabs to Wegovy pill kept losing weight https://news.ketelle.co.uk/stories/study-finds-people-switching-from-weight-loss-injections-to-pills-keep https://news.ketelle.co.uk/stories/study-finds-people-switching-from-weight-loss-injections-to-pills-keep Wed, 30 Sep 2026 17:40:34 +0100 Health Early real-world data from the OCTANE study, presented at the EASD meeting in Milan, suggests people who switched from GLP-1 injections to the Wegovy pill kept losing weight over about three months. The study is observational and its longer-term value is not yet established. (2 outlets: 1 left · 0 centre · 1 right) Late-stage trials show retatrutide cut body weight by up to about a quarter https://news.ketelle.co.uk/stories/late-stage-trial-results-published-for-lilly-s-retatrutide-weight-loss https://news.ketelle.co.uk/stories/late-stage-trial-results-published-for-lilly-s-retatrutide-weight-loss Wed, 30 Sep 2026 03:41:26 +0100 Health Eli Lilly's retatrutide produced the largest weight losses yet recorded in drug trials published on 29 September, in the Lancet (type 2 diabetes) and the New England Journal of Medicine (obesity). It is not yet approved anywhere. (5 outlets: 5 left · 0 centre · 0 right)